HL
Hongbo Lu
Director

Hongbo Lu insider trades: Arrowhead Pharmaceuticals (ARWR) stock buys and sales

Director, Arrowhead Pharmaceuticals Last trade May 12, 2026 26 Form 4 filings
$228K
Sold, last 12 months
1 sale
$1.6M
Bought, last 12 months
2 buys
11
Open-market trades
since 2019
5
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Hongbo reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 12, 2026ARWR↓ Sell$228K
Mar 31, 2026ZBIO↑ Buy$70K
Mar 31, 2026ZBIO↑ Buy$1.5M
Oct 7, 2025ZBIO↑ Buy$6.0M
Sep 13, 2024ZBIO↑ Buy$1000K
Sep 12, 2024TERN↑ Buy$5.0M
Mar 20, 2024ARWR↑ Buy$83K
Dec 23, 2022TERN↑ Buy$5.5M
Sep 7, 2022TERN↑ Buy$2.2M
Aug 16, 2022TERN↑ Buy$7.0M
Apr 22, 2019TPTX↑ Buy$1.1M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ARWR insiders

Open-market trades in the last 12 months

About Hongbo Lu's insider trades

Hongbo Lu is a director at Arrowhead Pharmaceuticals (ARWR). Since Apr 22, 2019, Hongbo has reported 10 open-market purchases worth $29.4M and 1 sale worth $228K on SEC Form 4. In the last 12 months: 2 buys ($1.6M) and 1 sale ($228K).

Their filings also include grants and awards (15 filings), other transactions (1 filing), shares returned to the company (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARWR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.